anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Problem Agitate Solution

Arc collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 26,550
Current window 20,791-20,820
Pages 885
Rows per page 30
Arc: Problem Agitate Solutionclear collectionreset all
18 30 60

Arc

20,791-20,820 of 26,550

filter-aware
07
The slide uses a process flow diagram to illustrate the company's core technology stack.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
08
Industry benchmarks based on Paul et al Nat Rev Drug Discov 2010.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
09
The chart highlights BenevolentAI's projected productivity (2023-2031) against established industry players.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
10
The slide uses a circular process diagram for the platform and a branching flow for the business model (A, B, C, D).BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
11
The chart uses a timeline-like progression (Target ID to Phase III) to visualize drug development stages.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
12
The slide uses a split-layout: left side defines the disease burden and market opportunity, right side defines the drug mechanism and target patient population.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
13
The slide includes explicit caveats regarding the small sample size and short duration of the Phase Ib study.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
14
The slide uses a split-layout with a summary of the collaboration on the left and a timeline/milestone tracker on the right.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
15
The slide uses a list-based structure to demonstrate the efficacy and speed of the AI platform, supported by external validation from The Lancet and Eli Lilly.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
16
The slide uses a hub-and-spoke diagram to link the company to its five strategic capital allocation pillars.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
17
The slide uses a horizontal timeline structure to map specific drug programs (BEN-2293, BEN-8744, etc.) against time-based milestones.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
03
The slide uses a comparison of protein structures to explain the mechanism of action for the therapeutic candidate.Larimar Therapeutics | Results Presentation Deck | 15 slides · Larimar Therapeutics
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
The slide uses a target icon to visually represent the 'objective' concept.Larimar Therapeutics | Results Presentation Deck | 15 slides · Larimar Therapeutics
Conference presentation Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
05
Larimar Therapeutics | Results Presentation Deck | 15 slidesLarimar Therapeutics | Results Presentation Deck | 15 slides · Larimar Therapeutics
Conference presentation Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
09
The table displays patient counts and percentages for various adverse events, including injection-site reactions.Larimar Therapeutics | Results Presentation Deck | 15 slides · Larimar Therapeutics
Conference presentation Investor relations Beat · SolutionLoop · Hypothesis Test1 hit
10
SAD = Single Ascending Dose study.Larimar Therapeutics | Results Presentation Deck | 15 slides · Larimar Therapeutics
Conference presentation Investor relations Beat · SolutionLoop · Hypothesis Test1 hit
11
MAD = Multiple Ascending Dose; SAD = Single Ascending Dose.Larimar Therapeutics | Results Presentation Deck | 15 slides · Larimar Therapeutics
Conference presentation Investor relations Beat · SolutionLoop · Hypothesis Test1 hit
12
The table details patient counts and percentages for various adverse events, including injection-site reactions.Larimar Therapeutics | Results Presentation Deck | 15 slides · Larimar Therapeutics
Conference presentation Investor relations Beat · SolutionLoop · Hypothesis Test1 hit
13
MAD = multiple ascending dose. Data points are estimated based on the three line charts provided.Larimar Therapeutics | Results Presentation Deck | 15 slides · Larimar Therapeutics
Conference presentation Investor relations Beat · SolutionLoop · Hypothesis Test1 hit
14
Data presented as median (range) for tmax and tlast, and geometric mean (geometric CV%) for Cmax and AUClast.Larimar Therapeutics | Results Presentation Deck | 15 slides · Larimar Therapeutics
Conference presentation Investor relations Beat · SolutionLoop · Hypothesis Test1 hit
15
Larimar Therapeutics | Results Presentation Deck | 15 slidesLarimar Therapeutics | Results Presentation Deck | 15 slides · Larimar Therapeutics
Conference presentation Investor relations Beat · Action1 hit
07
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Problem Statement1 hit
08
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Problem Statement1 hit
09
Source: Rahib et al, JAMA Net 2021Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Problem Statement1 hit
10
Uses a temple pillar metaphor to represent the evolution of cancer treatment options.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Problem Statement1 hit
18
The slide uses a biological process diagram to explain the therapeutic mechanism.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Proposed SolutionLoop · Logic Chain1 hit
19
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Proposed SolutionLoop · Logic Chain1 hit
20
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Proposed SolutionLoop · Logic Chain1 hit
21
The diagram uses a hub-and-spoke model to show iNKT cells at the center modulating innate (Dendritic, Macrophage, NK) and adaptive (T, B) cells.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Proposed SolutionLoop · Logic Chain1 hit
22
The slide uses a biological process diagram to explain the mechanism of action for iNKT cells.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Proposed SolutionLoop · Logic Chain1 hit